Research Article
Relationship between Clinicopathologic Variables in Breast Cancer Overall Survival Using Biogeography-Based Optimization Algorithm
Table 1
Comparison of clinicopathologic variables between the surviving and deceased patients.
| Variable | Total | Survival | Expired | p-value | N | % | N | % | N | % |
| Age (years) | | | | | | | 0.123 | ≤ 50 | 719 | 37.92 | 688 | 37.60 | 31 | 46.97 | | > 50 | 1177 | 62.08 | 1142 | 62.40 | 35 | 53.03 | | Grade | | | | | | | 0.122 | I, II | 1286 | 67.83 | 1247 | 68.14 | 39 | 59.09 | | III | 610 | 32.17 | 583 | 31.86 | 27 | 40.91 | | Her 2 | | | | | | | 0.040 | Negative | 1230 | 64.87 | 1195 | 65.30 | 35 | 65.30 | | Positive | 666 | 35.13 | 635 | 34.70 | 31 | 46.97 | | Estrogen receptor | | | | | | | <0.001 | Negative | 510 | 26.90 | 476 | 26.01 | 34 | 51.52 | | Positive | 1386 | 73.10 | 1354 | 73.99 | 32 | 48.48 | | Progesterone receptor | | | | | | | 0.001 | Negative | 701 | 36.97 | 664 | 36.28 | 37 | 56.06 | | Positive | 1195 | 63.03 | 1166 | 63.72 | 29 | 43.94 | | Tumor size (AJCC stage) | | | | | | | <0.001 | ≤ 2 cm | 1161 | 61.23 | 1142 | 62.40 | 19 | 28.79 | | > 2 cm | 735 | 38.77 | 688 | 37.60 | 47 | 71.21 | | Lymph node (AJCC stage) | | | | | | | <0.001 | Negative | 1265 | 33.72 | 1240 | 67.67 | 25 | 37.88 | | Positive | 631 | 33.28 | 590 | 32.24 | 41 | 62.12 | | Lymphovascular invasion | | | | | | | <0.001 | Negative | 1326 | 69.94 | 1293 | 70.66 | 33 | 50.00 | | Positive | 570 | 30.06 | 537 | 29.34 | 33 | 50.00 | | Dermal invasion | | | | | | | 0.009 | Negative | 1798 | 94.83 | 1740 | 95.08 | 58 | 87.88 | | Positive | 98 | 5.17 | 90 | 4.92 | 8 | 12.12 | | Perineural invasion | | | | | | | <0.001 | Negative | 1659 | 87.5 | 1610 | 87.98 | 49 | 74.24 | | Positive | 237 | 12.50 | 220 | 12.02 | 17 | 25.76 | | Surgery method | | | | | | | <0.001 | Partial mastectomy | 1133 | 59.76 | 1113 | 60.82 | 20 | 30.30 | | Total mastectomy | 763 | 40.24 | 717 | 39.18 | 46 | 69.70 | | Radiotherapy (RT) | | | | | | | 0.050 | With RT | 1194 | 62.97 | 1160 | 63.39 | 34 | 51.52 | | Without RT | 702 | 37.03 | 670 | 36.61 | 32 | 48.48 | | Chemotherapy | | | | | | | 0.004 | With CT | 1140 | 60.13 | 1089 | 59.51 | 51 | 77.27 | | Without CT | 756 | 39.87 | 741 | 40.49 | 15 | 22.73 | | Hormone therapy | | | | | | | <0.001 | With HT | 1265 | 69.13 | 28 | 42.42 | 1265 | 69.13 | | Without HT | 565 | 30.87 | 38 | 57.58 | 565 | 30.87 | | Target therapy | | | | | | | 0.232 | With TT | 302 | 15.93 | 288 | 15.74 | 14 | 21.21 | | Without TT | 1594 | 84.07 | 1542 | 84.26 | 52 | 78.79 | |
|
|
-value is estimated using the chi-squared test. HER2: human epidermal growth factor receptor 2. |